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Frailty in medically complex individuals with
chronic HIV
Susan Morgelloa,b, Gary Genslerc, Seth Shermanc, Ronald J. Ellisd,
Benjamin B. Gelmane, Dennis L. Kolsonf, Scott L. Letendreg,
Jessica Robinson-Pappa, Leah H. Rubinh, Elyse Singeri,
Miguel Valdes-Sueirasi, for the NNTC
Objectives: Multimorbidity and frailty are consequences of aging with HIV, yet not
everyone with medical disease is frail. Our objective was to identify factors associated
with frailty in a multimorbid HIV-infected cohort.
Design: Analysis of a prospective, observational, longitudinal cohort.
Methods: Three hundred and thirty-two participants in the medically advanced
National NeuroAIDS Tissue Consortium (NNTC) study were categorized as frail,
prefrail, or robust with the Fried Frailty Index. A series of logistic regression analyses
(first univariate, then multivariable) were conducted to determine whether medical
comorbidities, immunologic and virologic parameters, and/or neuropsychiatric vari-
ables predicted increased odds of frailty.
Results: The mean number of medical comorbidities per participant was 2.7, mean
CD4þ T-cell count was 530 cells/ml, and 77% had undetectable HIV RNA in blood.
Twenty-two percent were frail, 55% prefrail, and 23% robust. Significant predictors of
frailty in multivariable analysis were cognitive diagnosis rendered by Frascati criteria,
depressive symptoms, diabetes mellitus, chronic obstructive pulmonary disease
(COPD), and sex. Men were less likely to be frail than women. Higher odds of frailty
were seen with: symptomatic, but not asymptomatic, cognitive impairment (compared
with cognitive normals); more depressive symptoms; diabetes mellitus; and COPD.
Conclusion: Neuropsychiatric illness increased odds of being frail on a predominantly
physical/motoric measure, but only when symptomatic. Lack of association with
asymptomatic impairment may reflect the importance of functional limitation to frailty,
or possibly a unique resilience phenotype. Understanding why sex and symptomatic
neuropsychiatric illness are associated with frailty will be important in managing HIV-
associated morbidity in aging populations.
Copyright  2019 Wolters Kluwer Health, Inc. All rights reserved.
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Introduction
Medical illness accrues with age, yet for each level of
comorbidity burden, individual medical outcomes are
variable. Frailty is a phenotype that accounts for some of
this variability; within each stratum of disability, frailty
predicts survival [1,2]. Adults living with HIV exhibit
frailty more frequently than HIV-negative individuals of
similar age, but whether this increase is a consequence of
HIV itself or of its comorbidities is debated [3,4]. Some
also question the validity of frailty measurement tools in
populations with mean ages under 50 [3,4]. As
combination antiretroviral therapy (cART)-era HIV
populations enter decades for which common frailty
measures were designed, determinants of frailty will be
important to identify in order to optimize clinical
management.
The most widely deployed and validated instrument to
measure frailty in HIV-positive and HIV-negative
populations has been the Fried Frailty Index (FFI),
which is heavily weighted to physical characteristics, but
lacks measures of cognition, disability, and comorbidity
[5,6]. Accordingly, studies have investigated the relation-
ship between FFI and these other components. In the
context of HIV, the Study to Understand the Natural
History of HIVand AIDS in the Era of Effective Therapy
(SUN study) assessed comorbidity burden by the Veterans
Aging Cohort Study (VACS) index [7]. Comorbidity was
related to frailty and prefrailty, but transitions in frailty
status were not reflected by changes in VACS index values
[7]. Multimorbidity, defined as three or more medical
illnesses, was correlated with frailty in a sample of people
living with HIV (PLWH) visiting a metabolic clinic in
Italy [8]. In a functionally intact [i.e. without impairments
in activities of daily living (ADL)] subsample from this
clinic, cognitive status assessed by three neuropsychologic
tests, and depressive symptom index was also correlated
with frailty status [9]. In a sample from a tertiary care
center in Mexico that excluded severe illnesses, such as
COPD and advanced cardiac disease, frailty was related to
functional cognitive impairments assessed with the
NEUROPSI battery [10]. In an AIDS Clinical Trials
Group (ACTG) longitudinal observational study (ACTG
A5001), cognitive impairment was associated with frailty,
and when present in combination, resulted in a greater
risk of falls, disability, or death than either factor alone
[11].
To date, no studies have examined the simultaneous
relationships between frailty status and neuropsychiatric
dysfunction, medical illness, and immune and virologic
biomarkers in an aging HIV cohort. As increased medical
illness burden is usually an inevitable consequence of
aging, we sought to determine the factors associated with
frailty in a highly multimorbid sample of aging PLWH.
Analysis of a multimorbid patient population allowed
identification of specific illnesses or factors that increased
the likelihood of frailty when individuals had already
attained a state of medical compromise. Furthermore, as
cognitive abnormalities without functional impairment
(asymptomatic neurocognitive impairment, ANI) are
common in PLWH, we wanted to ascertain whether ANI
was associated with frailty on a medically morbid
background, as this could have implications for clinical
screening [12].
Methods
Patient population
The National NeuroAIDS Tissue Consortium (NNTC)
is a longitudinal cohort and organ donation study, whose
mission is to serve as a research resource providing tissue
and fluid biospecimens from well characterized HIV-
infected individuals. Participants for this analysis were
enrolled at the four clinical sites of NNTC, located at
Galveston, Texas; Los Angeles, California; New York
City, New York; and San Diego, California. Participants
were part of the ongoing, longitudinal study conducted
under oversight of eachmedical center’s local Institutional
Review Board. All participants consented to the use of
their data for the purposes of HIV and neuroHIV
research. All informed consent procedures included tests
of comprehension to ensure cognitively impaired
participants were able to consent. Criteria for entry into
the NNTC study include willingness to be an organ
donor upon demise, and neuromedical conditions for
which adequate or curative therapy is unavailable, thus
enriching the cohort for significant medical morbidity.
Qualifying medical conditions include illnesses, such as
solid organ or hematologic cancers, advanced liver
disease, and significant cardiac disease, but are not limited
to these categories and are at the discretion of NNTC site
PIs. In the most recent 5-year cycle, advanced age (60
years or older) was added to the list of qualifying
conditions, enabling NNTC to support a research focus
on aging. Exclusion criteria for NNTC include
unwillingness to be a brain donor upon demise, and
age under 18 years (the age of consent for organ
donation).
Participants were included in this analysis if the central
NNTC database, located at Emmes Corporation in
Rockville, Maryland, contained a complete FFI assess-
ment collected between 2014 and 2018, along with a full
elaboration of neuromedical disorders active at the time of
assessment. Assessments with missing values were not
included. Of 603 participants active in the study, 332 met
this criteria, and additional information from standard-
ized NNTC evaluations was collected and analyzed, as
described below. Analyses were conducted on all
individuals with available data, and not on the basis of
representativeness of the active cohort, as we did not have
any a priori hypotheses to test regarding which factors
1604 AIDS 2019, Vol 33 No 10
 Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.
would be associated with frailty. At the time of analysis,
the demographic composition of the larger cohort from
which the sample was selected was: 77% male, 23%
female; 29% African American, 30% Hispanic, 36%
Caucasian, 5% other race; and 20% intravenous drug use
(IVDU) risk for HIV.
Neuromedical assessment
Participants in the NNTC receive a multimodal
evaluation that includes: laboratory analysis to determine
current CD4þ T-cell count and plasma HIVRNA (lower
limit of quantitation was set at 40 copies/ml); review of all
current medications including cART and adherence;
review of medical illnesses, inclusive of hypertension
(HTN), diabetes mellitus, hyperlipidemia, viral hepatitis,
chronic renal disease, cardiac disease, chronic obstructive
pulmonary disease (COPD), non-AIDS defining cancers,
cerebrovascular disease, and lipodystrophy; review of
other medical and behavioral symptoms (as for example,
weight loss, apathy, fever); review of recent tobacco
smoking; and neurologic examination to evaluate signs
and symptoms of distal symmetric polyneuropathy
(DSPN), and other significant neurologic disorders.
Specific medical illnesses for review were selected on the
basis of their general prevalence in HIV, and because they
collectively accounted for themajority of illness burden in
NNTC. Information was collected both from participant
examination, participant interview, and whenever avail-
able, caregiver interview and review of the medical
record.
Neurobehavioral assessment
The NNTC neuropsychological test battery has been
previously published; in brief, a battery of tests is
administered to examine global cognitive function and
the following seven putative cognitive domains: learning;
memory; abstraction/executive functioning; speed of
information processing; verbal fluency; working mem-
ory; and motor [13]. Global and domain T scores are
calculated and used to derive clinical ratings. Functional
impacts are assessed through a modified Lawton and
Brody ADL questionnaire and the Patient’s Assessment of
Own Functioning Inventory (PAOFI), and cognitive
diagnoses are assigned at clinical sites by experienced
neuropsychologists according to the research nosology for
diagnosis of HIV-associated neurocognitive disorders
(HAND) established in Frascati [14]. This nosology
results in the following sub-categories: asymptomatic
neurocognitive impairment (ANI), mild neurocognitive
disorder (MND), HIV-associated dementia (HAD), and
cognitive impairment because of other causes (NPI-O).
Cognitive assessments were utilized only if they occurred
in the same study visit as the FFI and neuromedical
assessment; for 16 individuals, a Frascati diagnosis was not
available in this interval. A structured psychiatric
interview (the Composite International Diagnostic
Interview version 2.1) is conducted, and depressive
symptoms quantified by administration of the Beck
Depression Inventory (BDI) version 2. Depressive
symptom scores were utilized only if they occurred in
the same study visit as the FFI and neuromedical
assessment; for 17 individuals, a BDI score was not
available in this interval.
Frailty assessment
Administration of the FFI at each site was standardized,
and presence or absence of criteria in its five dimensions
(weight loss, exhaustion, grip strength, physical activity,
timed walk) were recorded. Participants were classified as
frail when they had three or more positive criteria;
prefrail with one or two criteria; and robust when no
criteria were present.
Statistical modeling and analysis
Frailty status was modeled as an ordinal outcome.
Cumulative logistic regression analysis (SAS 9.4 proce-
dure LOGISTIC) was used to determine statistical
significance, odds ratios (ORs), and 95% confidence
intervals (CIs) for associations between potential risk
factors and all frailty outcomes. Each factor was initially
modeled in a univariate setting against frailty status;
factors significant at P¼ 0.10 or less were retained for a
multivariable model. In the multivariable model, factors
were removed via backward elimination until all
remaining factors were statistically significant at
P¼ 0.05 or less. ORs and 95% CIs were computed for
these factors for each frailty outcome model. Analyses
were not adjusted for multiple comparisons. Potential risk
factors assessed in the initial univariate analyses included:
age, race/ethnicity, sex, IVDU/sexual risk factor for HIV
acquisition, current and nadir CD4þ T-cell count, plasma
HIV RNA, medical illnesses (described above), smoking,
presence of DSPN, cognitive diagnosis rendered via
Frascati criteria, depressive symptom score from the BDI,
use of antidepressant medication, BMI, literacy level
assessed by the Wide Range Achievement Test – version
3 (WRAT-3), and study site.
Secondary analyses included: tests of association with
individual components of the FFI; tests of association
between each nonnormal Frascati diagnosis vs. unim-
paired; a univariate analysis of global T-score on frailty
outcomes; and a multivariable analysis of individual
domainT-scores without adjustments for other factors. As
with other multivariable models, factors were removed
via backward elimination until all remaining factors were
significant at P less than 0.05.
Results
Cohort characteristics
The study population was demographically diverse: there
was relatively equal distribution of African American,
Hispanic, and Caucasian race/ethnicity, and 28% were
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women. Although most of the population had a low nadir
CD4þT-cell count, the mean current CD4þT-cell count
was 530 cells/ml. Median plasma HIV RNA was
undetectable (77% of the sample). There was a significant
burden of medical comorbidities, with an average of 2.7
medical conditions per person (median 3, IQR [1–4]).
Almost one-half of the sample smoked, had hypertension,
and hyperlipidemia, and over one-half displayed DSPN.
Depressive symptoms were generally within the minimal
to mild range; 38% of the sample was actively prescribed
antidepressant medication. Thirty-five percent of the
sample was cognitively normal, with ANI in 14% and
symptomatic cognitive impairments in 51% (21% MND,
11% HAD, 19% NPI-O) (Table 1).
Associations with overall frailty
Twenty-two percent of the population was frail, 55%
prefrail, and 23% robust. The frequency of abnormal FFI
components included: 15% weight loss, 40% exhaustion,
35% decreased grip strength, 29% reduced physical
activity, and 30% abnormal timed walk. In univariate
analyses, overall frailty status was associated with sex,
diabetes mellitus, COPD, depressive symptoms, and
cognitive diagnosis at the P 0.01 or less level; with DSPN
and use of antidepressant medication at the P¼ 0.05 or
less level; and with BMI and cancer diagnosis at P value
0.10 or less. In the multivariable model, female sex [OR
for men 0.58 (95% CI: 0.35–0.97), P¼ 0.04], more
depressive symptoms [OR 1.07 per unit BDI (95% CI:
1.05–1.10), P< 0.01], cognitive abnormality [symptom-
atic impairment vs. normal cognition OR 2.35 (95% CI:
1.39–3.99), P< 0.01], and the presence of diabetes
mellitus [OR 1.81 (95% CI: 1.02–3.22), P¼ 0.04] or
COPD [OR 1.94 (95% CI: 1.03–3.66), P¼ 0.04) were
associated with frailty (model r2 0.27, P< 0.01). Viral
suppression had no effect in the model. The proportional
odds assumption was met (P¼ 0.51). Twenty-nine
percent of women were frail in contrast to 19% of
men; 30% of those with diabetes mellitus were frail in
contrast to 20% of those without; 32% of those with
COPDwere frail in contrast to 20% of those without; the
mean BDI in the frail was 15.9 in contrast to 5.4 in the
robust (38% of those with a BDI score 14 – the
threshold for mild depression – were frail compared with
14% of those with BDI < 14); and 32% of those with
symptomatic cognitive impairment were frail in contrast
to 13% of cognitive normals (Tables 1 and 2).
Associations with frailty components
In multivariable analysis (Table 2), depressive symptoms
had the most consistent associations with FFI compo-
nents, significant in all except grip strength. Other factors
1606 AIDS 2019, Vol 33 No 10
Table 1. Participant characteristics.
Total Robust Prefrail Frail P
Sample size, N (%) 332 78 (23%) 181 (55%) 73 (22%) n/a
Mean age (SD) 59.7 (8.9) 58.9 (9.4) 59.5 (8.2) 60.8 (9.9) 0.36
Male sex 72% 85% 71% 63% <0.01
Race/ethnicity 0.5
African American 29% 27% 33% 21%
Hispanic 32% 35% 28% 38%
Caucasian 34% 33% 33% 37%
Other 5% 5% 6% 4%
IVDU risk 23% 21% 21% 29% 0.17
Mean current CD4þ cell count (SD) 530 (299) 489 (299) 552 (314) 520 (257) 0.29
Median nadir CD4þ cell count [IQR] 50 [8–180] 45 [6–145] 65 [7–190] 50 [12–149] 0.55
Median log plasma HIV load [IQR] 1.6 [1.6–1.6] 1.6 [1.6–1.6] 1.6 [1.6–1.6] 1.6 [1.6–1.6] 0.93
Tobacco smoking 46% 35% 52% 44% 0.03
Hypertension 46% 45% 44% 53% 0.36
Diabetes mellitus 20% 6% 23% 27% <0.01
Hyperlipidemia 48% 50% 49% 47% 0.91
Viral hepatitis 21% 22% 19% 23% 0.76
Chronic renal disease 10% 9% 8% 15% 0.25
Cardiac disease 20% 19% 18% 25% 0.45
Chronic obstructive pulmonary disease 15% 6% 16% 22% 0.03
Cerebrovascular disease 17% 10% 19% 18% 0.23
Non-AIDS defining cancer 14% 13% 12% 21% 0.17
Lipodystrophy 11% 10% 13% 8% 0.57
Peripheral neuropathy 58% 51% 58% 69% 0.15
BMI (mean) 27.1 (6.4) 25.7 (4.6) 27.6 (7.2) 27.5 (5.7) 0.07
WRAT-3 raw score (mean) 44.8 (9.0) 44.3 (8.5) 44.9 (9.2) 45.0 (9.1) 0.88
Beck Depression Inventory (median) 8 [2–16] 3 [0–9] 8 [2–16] 16 [7–22] <0.01
Antidepressant medication use 38% 30% 37% 46% 0.12
Cognitive diagnosis <0.01
Normal 35% 47% 35% 21%
Asymptomatic impairment (ANI) 14% 24% 15% 3%
Mild neurocognitive disorder (MND) 21% 16% 20% 29%
HIV-associated dementia (HAD) 11% 3% 11% 21%
Impairment because of other causes (NPI-O) 19% 10% 19% 26%
Percentages represent within frailty category totals. IQR, interquartile range. Bold indicates P values less than 0.05.
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significantly associated with FFI components after
multivariable analysis were for the most part conceptually
congruent: for example, weight loss was associated with
smoking and cancer, worse physical activity and
exhaustion with increased BMI, and worse physical
activity with COPD.
Neurobehavioral associations with frailty
As neurobehavioral abnormalities had the greatest and
most consistent associations with frailty and individual
FFI components, the next set of analyses examined these
associations. First, for the 104 individuals who had a BDI
value in the range of depression (BDI 14), the use of
antidepressant medication (55% of this sub-sample of 104)
was not associated with a greater or lesser percentage
of frailty.
We then examined which cognitive diagnoses displayed
associations with frailty, and within the entire range of
diagnoses, whether any particular neuropsychological
domains (particularly motor domain, given the physical
emphasis of FFI) accounted for significant associations.
With regard to diagnoses, only symptomatic cognitive
abnormalities, and not asymptomatic, were associated
with frailty [ORs: 2.6 (MND), 5.2 (HAD), and 3.0 (NPI-
O), all P values< 0.01] (Table 3 and Fig. 1). Individuals
with ANI could not be distinguished from those with
normal cognition with regard to the odds of being frail, or
with regard to the odds of abnormality on any individual
frailty component (Table 3). Those with ANI, while
accounting for 14% of the overall sample, accounted for
only 3% of those who were frail, whereas all other
cognitive categories (including normal) accounted for
over 20% of those with frailty (Table 1). The group with
ANI could not be distinguished from other cognitive
categories on the basis of their number of medical
comorbidities. With regard to depressive symptoms, they
were similar to both the cognitively normal group and
those with NPI-O (mean BDI score 8.6, 9.4, and 7.0 for
normal, NPI-O, and ANI, respectively), with more
depressive symptoms in MND (mean score 14.3) and
HAD (mean score 15.1) (overall ANOVA P< 0.01). The
group with ANI had a similar proportion of women
compared with other cognitive categories (27.9%), but
displayed low prevalence of diabetes mellitus (11.6%) and
COPD (4.7%).
Global T scores were associated with frailty and all its
components except weight loss (higher T scores indicate
better function; significant odds ratios ranged from 0.94
to 0.97, with P values 0.02). In the model predicting
overall frailty using neuropsychological domain scores
(but not the global score), only motor domain remained
significant (OR 0.95 [95% CI 0.94–0.97], P< 0.01); that
is, other domains did not make independent contribu-
tions to frailty when the motor score was accounted for.
Domain associations with individual frailty components
are reported in Table 3.
Frailty in HIV Morgello et al. 1607
T
ab
le
2
.
Fa
ct
o
rs
co
rr
el
at
ed
w
it
h
fr
ai
lt
y
an
d
it
s
in
d
iv
id
u
al
co
m
p
o
n
en
ts
.
O
ve
ra
ll
Fr
ai
lt
y
co
m
p
o
n
en
t
O
R
(9
5
%
C
I)
Fa
ct
o
r
Fr
ai
lt
ya
O
R
(9
5
%
C
I)
W
ei
gh
t
lo
ss
Ex
h
au
st
io
n
P
h
ys
ic
al
ac
ti
vi
ty
T
im
ed
w
al
k
G
ri
p
st
re
n
gt
h
G
en
d
er
(m
al
e)
0
.5
8
(0
.3
5
–
0
.9
7
)b
B
D
I
to
ta
l
sc
o
re
1
.0
7
(1
.0
5
–
1
.1
0
)d
1
.0
6
(1
.0
2
–
1
.0
9
)d
1
.1
3
(1
.0
9
–
1
.1
7
)d
1
.0
4
(1
.0
1
–
1
.0
6
)c
1
.0
4
(1
.0
0
–
1
.0
7
)b
Fr
as
ca
ti
d
ia
gn
o
si
s
2
.3
5
(1
.3
9
–
3
.9
9
)c
2
.3
0
(1
.3
5
–
3
.9
2
)c
(M
N
D
/H
A
D
/N
P
I-
O
vs
.
N
L)
P
er
ip
h
er
al
n
eu
ro
p
at
h
y
1
.9
6
(1
.0
3
–
3
.7
6
)b
D
M
1
.8
1
(1
.0
2
–
3
.2
2
)b
2
.5
0
(1
.2
3
–
5
.0
7
)b
C
O
P
D
1
.9
4
(1
.0
3
–
3
.6
6
)b
2
.3
4
(1
.2
3
–
4
.4
2
)c
N
o
n
-A
ID
S
d
efi
n
in
g
ca
n
ce
r
2
.9
1
(1
.3
2
–
6
.3
8
)c
2
.4
7
(1
.0
7
–
5
.7
3
)b
Li
p
o
d
ys
tr
o
p
h
y
0
.2
8
(0
.1
1
–
0
.7
1
)c
T
o
b
ac
co
sm
o
ki
n
g
1
.9
6
(1
.0
2
–
3
.7
8
)b
B
M
I
1
.0
5
(1
.0
1
–
1
.0
9
)c
1
.0
4
(1
.0
0
–
1
.0
8
)b
B
D
I,
B
ec
k
D
ep
re
ss
io
n
In
ve
n
to
ry
;C
I,
co
n
fi
d
en
ce
in
te
rv
al
;C
O
P
D
,c
h
ro
n
ic
o
b
st
ru
ct
iv
e
p
u
lm
o
n
ar
y
d
is
ea
se
;D
M
,d
ia
b
et
es
m
el
li
tu
s;
H
A
D
,H
IV
-a
ss
o
ci
at
ed
d
em
en
ti
a;
M
N
D
,m
il
d
n
eu
ro
co
gn
it
iv
e
d
is
o
rd
er
;
N
P
I-
O
,
co
gn
it
iv
e
im
p
ai
rm
en
t
b
ec
au
se
o
f
o
th
er
ca
u
se
s;
O
R
,
o
d
d
s
ra
ti
o
.
a
P
ar
ti
ci
p
an
ts
ch
ar
ac
te
ri
ze
d
as
ro
b
u
st
,
p
re
fr
ai
l,
o
r
fr
ai
l.
b
Fa
ct
o
r
si
gn
ifi
ca
n
t
at
0
.0
1
<
P
<
0
.0
5
.
c
Fa
ct
o
r
si
gn
ifi
ca
n
t
at
0
.0
0
1
<
P
<
0
.0
1
.
d
Fa
ct
o
r
si
gn
ifi
ca
n
t
at
P
le
ss
th
an
0
.0
0
1
.
 Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.
Sex and frailty
As women had greater odds of being frail when all factors
were considered, we examined sex differences in the
sample to gain insight into this association. Although most
of thewomen (74%)were located in theNewYorkNNTC
site, therewas no site-specific associationwith frailty status.
Women were more often African American (43 vs. 23%)
and less often Caucasian (18 vs. 40%) than men (P< 0.01),
1608 AIDS 2019, Vol 33 No 10
Fig. 1. Distribution of frailty phenotypes by cognitive diagnosis. Percentage of individuals with frail, pre-frail, or robust status
within each diagnostic cognitive category. NL: Cognitively normal; ANI: asymptomatic neurocognitive disorder; MND: mild
neurocognitive disorder; HAD: HIV-associated dementia; NPI-O: cognitive impairment due to other (non HIV) causes.
Table 3. Cognitive associations with frailty and its components.
Frailty component OR (95% CI)
Cognitive diagnosis
(reference: normal)
Frailty OR
(95% CI)
Weight
loss Exhaustion
Physical
activity Timed walk Grip strength
ANI NS NS NS NS NS NS
MND 2.6 (1.4–3.8)b NS 2.6 (1.4–4.8)b NS NS 2.0 (1.0–3.9)a
HAD 5.2 (2.4–11.2)c NS 2.6 (1.2–5.7)a 4.4 (1.9–9.9)c 2.3 (1.0–5.2)a 2.5 (1.1–5.6)a
NPI-O 3.0 (1.6–5.8)c NS NS NS 2.4 (1.2–4.8)a 2.5 (1.3–5.0)b
Cognitive Domain T
score
Global T Scored 0.94 (0.92–0.97)c NS 0.96 (0.93–0.99)b 0.96 (0.93–0.99)b 0.94 (0.91–0.97)c 0.97 (0.94–0.99)a
Abstraction executive
function domain
NS 0.97
(0.94–1.00)a
NS NS NS NS
Memory domain NS NS 0.96 (0.94–0.99)b NS NS NS
Verbal fluency domain NS NS NS 0.97 (0.95–0.99)b NS NS
Motor domain 0.95 (0.94–0.97)c NS NS NS 0.94 (0.92–0.97)c 0.96 (0.94–0.98)c
ANI, asymptomatic neurocognitive impairment; HAD, HIV-associated dementia; MND, mild neurocognitive disorder; NPI-O, cognitive
impairment because of other causes; NS, not significant at P less than 0.05; OR, odds ratio.
aFactor significant at 0.01<P<0.05.
bFactor significant at 0.001<P<0.01.
cFactor significant at P less than 0.001.
dGlobal T score was modeled individually, and not in conjunction with domain scores.
 Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.
but race/ethnicity was not associated with frailty. Women
in this sample had higher CD4þ T-cell counts and nadirs
than men [CD4þ T-cell count 617 (31 SEM) vs. 496
(19 SEM) cells/ml, P< 0.01; nadir 151 (17 SEM) cells/ml
vs. 102 (10 SEM) cells/ml, P< 0.01)]; again, factors not
associated with frailty.Women also had a greater frequency
of diabetesmellitus (33 vs. 15%,P¼ 0.03), and higher BMI
[29.9 (0.6 SEM) vs. 26.1 (0.4 SEM), P< 0.01].
Discussion
Frailty is a useful construct across diverse medical
conditions and populations, as it is an indicator of
decreased physiologic reserve predicting morbidity and
mortality in the face of stressors, and can be used to guide
therapy for medical disease [1,2,15]. It is thought that HIV
is an independent risk factor for frailty, supported by
observations of increased prevalence in HIV cohorts
equivalent to older HIV-negative populations [3,16].
However, PLWH also experience rates of medical illnesses
comparable with older HIV negative adults, and medical
multimorbidity is associated with frailty in many popula-
tions regardless of serostatus [4,8,17]. Accordingly, the
purpose of this study was to evaluate conditions associated
with frailtywithin the context ofmultimorbidity using data
from theNNTCcohort, which is a population selected for
serious medical disorders.
In our study, neuropsychiatric illness, manifested by
depressive symptoms and functional cognitive
impairment, was significantly associated with frailty and
its components. No consensus currently exists for an
operational definition of frailty, and many have suggested
that measures of mental health should be included [18].
Our findings support this suggestion, and are consistent
with prior studies in HIV demonstrating an association
between neuropsychiatric abnormality and frailty status
[9,10]. Although the underlying mechanism of this
association cannot be determined in our study, prior
studies have demonstrated an association between motor
abnormality (and with particular relevance to frailty,
abnormal gait) and cognitive impairment, both in PLWH
and HIV-negative populations [19–21]. In turn, motor
and cognitive abnormalities may be correlated with
cerebral white matter disease on neuroimaging [22–24].
Thus, it could be hypothesized that cerebral disorders
impacting connectivity between brain regions via white
matter abnormality form a common basis for both motor
aspects of frailty and abnormal cognition.
Our study also demonstrates that asymptomatic cognitive
impairments are not associated with frailty; lack of
association between ANI and frailty has been previously
noted in a population from Mexico City [10]. Although
the group with ANI in our study had a low prevalence of
frailty, they also had low frequencies of other frailty-
associated factors, such as diabetes mellitus, COPD, and
depressive symptoms. There is controversy surrounding
ANI; some suggest that mild disorders based solely on
cognitive testing may represent a form of false positive
HANDdiagnosis; others, that individuals with ANI have a
unique neurobiology manifesting an increased risk of
progression to symptomatic HAND [25–29]. It is also
possible that individuals with ANI have an abnormal
neurobiology dissimilar to other forms of HAND.
Pertinent to a hypothesis implicating white matter
abnormality in the generation of motor deficits and frailty,
a recent study demonstrated that neuroradiographic white
matter abnormalities in ANI could be distinguished from
patterns in cognitive normals and in MND [29]. Pertinent
to frailty measures, individuals with ANI may not display
HIV-associated motor abnormalities. In a study of motor
correlates of HAND, ANI was similar to cognitive normal
in its lack of motor manifestations, whereas all forms of
syndromic HAND displayed greater motor impairments
[19]. However, it is also possible that ANI represents a
resilience phenotype in the face of a deleterious
neurobiological process in the continuum of HAND.
These may be individuals who maintain functionality and
resist frailty, despite a significant burden of HIV-associated
brain disease. Continued monitoring of our cohort over
time should determine whether individuals with ANI
show adverse medical and cognitive outcomes, or
progression in their frailty phenotypes.
With regard to other cognitive diagnoses, individuals
with the most severe form of impairment (HAD)
displayed the greatest odds of frailty, and with the
exception of weight loss, pervasive association with all
FFI components. The milder MND and NPI-O had
smaller odds ratios for frailty phenotype, shared an
association with grip strength, and differed with regard to
associations with exhaustion and timed walk.
Frailty in our cohort was also characterized by a pervasive
relationship with depressive symptoms. Antidepressant
medication did not appear to influence this relationship.
The association with depressive symptoms was seen not
only with overall frailty phenotype but also with all frailty
components except grip strength. The significance of this
association is unclear; depressive phenomena are com-
mon correlates of a wide spectrum of neurodegenerative
disorders, but are also encountered with medical illness
and loss of physical function. Whether this association
reflects a causative or reactive phenomenon, or is simply a
correlation in the absence of a primary pathogenetic
mechanism, is unclear. Regardless of pathogenesis, the
association of neurobehavioral phenomena (cognition,
depression) with frailty in HIV suggests that these should
be accounted for in future studies of frailty conducted
with regard to single medical disease outcomes.
With regard to the diverse medical disorders encountered
in our population, diabetes mellitus and COPD were
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independently associated with frailty. In the National
Health and Nutrition Examination Survey (NHANES),
56.6% of individuals with COPD were frail, and this
association has received significant attention [30]. It was
observed that individuals with COPD had more than
double the number of medical comorbidities than those
without [30]. In our cohort individuals with COPD had
significantly more medical illnesses than those without
(4.4 vs. 2.4, P< 0.01). However, COPD was not unique:
the same was true for every medical condition examined.
For example, individuals with renal disease in the NNTC
had an average of 4.5 medical illnesses in comparison to
2.5 in those without; yet, renal disease did not increase the
odds of frailty. The association of diabetes mellitus and
frailty has been previously observed, and is hypothesized
to reflect an ‘accelerated aging’ process in this disorder, or
alternatively, complications, such as renal dysfunction
[31]. In our cohort, renal disease was not a plausible
mechanistic pathway for frailty, and in the absence of
biomarkers, we cannot comment on ‘accelerated aging’.
Finally,women in our cohort had greaterodds of being frail
than men, which is similar to general populations, where
female sex is associated with frailty [32]. In the Women’s
InteragencyHIV Study (WIHS), it has been suggested that
social and behavioral risk factors are important in the
occurrence of frailty [32]. The WIHS is not selected for
medical morbidity, with an overall frailty prevalence of
10%, less than half of what is seen in thewomen ofNNTC.
The NNTC study was not designed to examine social or
cultural/behavioral factors, and this is an important area for
future investigation, as issues such as socioeconomic status,
healthcare access and utilization, and other behaviors and
belief systems, could play a role in the development of
frailty. Alternatively, it is possible that biological factors not
routinely ascertained in NNTC could play a role, such as
hormonal status, bone mineral density, and a more general
burden of central nervous system (CNS) active medica-
tions, such as antipsychotics, sedatives, and anxiolytics.
Further study is warranted to explain this sex disparity.
In summary, the NNTC cohort provides a unique
opportunity to study frailty in the context of medical
multimorbidity, and demonstrates the importance of
symptomatic neuropsychiatric dysfunction to the frailty
phenotype. It also raises questions with regard to why
women and particular medical illnesses have increased odds
of frailty, and suggests that further study will be necessary to
determine if there aremodifiable aspects of these associations
that can improve outcomes for adults aging with HIV.
Acknowledgements
Author contributions: S.M.: conception and design of
study, acquisition of data, interpretation, drafting of work;
G.G.: design of study, statistical analysis, drafting of work;
S.S.: design of study, statistical analysis, drafting of work;
R.J.E.: conception and design of study, interpretation,
drafting of work; B.B.G.: conception and design of study,
acquisition of data, interpretation, drafting of work;
D.L.K.: conception and design of study, interpretation,
drafting of work; S.L.L.: conception and design of study,
interpretation, drafting of work; J.R.-P.: conception and
design of study, interpretation, drafting of work; L.H.R.:
design of study, analysis, interpretation, drafting of work;
E.S.: conception and design of study, acquisition of data,
interpretation, drafting of work; M.V.-S.: acquisition of
data, interpretation, drafting of work.
Supported by the National Institutes of Health:
Manhattan HIV Brain Bank (U24MH100931); Texas
NeuroAIDS Research Center (U24MH100930);
National Neurological AIDS Bank (U24MH100929);
California NeuroAIDS Tissue Network
(U24MH100928); NNTC Data Coordinating Center
(U24MH100925); Motor dysfunction in cART-era HIV:
Neural circuitry and pathogenesis (RO1NS108801).
Conflicts of interest
There are no conflicts of interest.
References
1. Rockwood K, Andrew M, Mitnitski A. A comparison of two
approaches to measuring frailty in elderly people. J Gerontol
Med Sci A 2007; 62:738–743.
2. Kelly SG, Wu K, Tassiopoulos K, Erlandson KM, Koletar SL,
Palella FJ for the ACTG A5322 Study team. Frailty is an in-
dependent risk factor for mortality, cardiovascular disease,
bone disease, and diabetes among aging adults with HIV. Clin
Infect Dis 2018. doi: 10.1093/cid/ciy1101. [Epub ahead of
print].
3. Levett TJ, Cresswell FV, Malik MA, Fisher M, Wright J. Systema-
tic review of prevalence and predictors of frailty in individuals
with human immunodeficiency virus. J Am Geriatr Soc 2016;
64:1006–1014.
4. Engel T, Raffenberg M, Marzolini C, Cavassini M, Kovari H,
Hasse B, Tarr PE. HIV and aging – perhaps not as dramatic as
we feared? Gerontology 2018; 64:446–456.
5. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C,
Gottdiener J, et al. Frailty in older adults: evidence for a
phenotype. J Gerontol Med Sci A 2001; 56:M146–M156.
6. Bouillon K, Kivimaki M, Hamer M, Sabia S, Fransson EI, Singh-
Manoux A, et al. Measures of frailty in population-based
studies: an overview. BMC Geriatr 2013; 13:64.
7. Escota GV, Patel P, Brooks JT, Bush T, Conley L, Baker J, et al.,
SUN Study Investigators. The Veterans Aging Cohort Study
Index is an effective tool to assess baseline frailty status in a
contemporary cohort of HIV-infected persons. AIDS Res Hum
Retroviruses 2015; 31:313–317.
8. Guaraldi G, Malagoli A, Theou O, Brothers TD, Wallace LMK,
Torelli R, et al. Correlates of frailty phenotype and frailty index
and their associations with clinical outcomes. HIV Medicine
2017; 18:764–771.
9. Wallace LMK, Ferrara M, Brothers TD, Garlassi S, Kirkland SA,
Theou O, et al. Lower frailty is associated with successful
cognitive aging among older adults with HIV. AIDS Res
Hum Retroviruses 2017; 33:157–163.
10. Zamudio-Rodriguez A, Belaunzaran-Zamudio PF, Sierra-Ma-
dero JG, Cuellar-Rodriguez J, Crabtree-Ramirez BE, Alcala-
Zermeno JL, et al. Association between frailty and HIV-asso-
ciated neurodegenerative disorders among older adults living
with HIV. AIDS Res Hum Retroviruses 2018; 34:449–455.
1610 AIDS 2019, Vol 33 No 10
 Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.
11. Erlandson KM, Perez J, Abdo M, Robertson K, Ellis RJ, Koletar
SL, et al. Frailty, neurocognitive impairment, or both in
predicting poor health outcomes among adults living with
human immunodeficiency virus. Clin Infect Dis 2019;
68:131–138.
12. Heaton RK, Clifford DB, Franklin DO Jr, Woods SP, Ake C,
Vaida F, et al., CHARTER Group. HIV-associated neuro-
cognitive disorders persist in the era of potent antiretro-
viral therapy: CHARTER study. Neurology 2010; 75:2087–
2096.
13. Woods SP, Rippeth JD, Frol AB, Levy JK, Ryan E, Soukup VM,
et al. Interrater reliability of clinical ratings and neurocog-
nitive diagnoses in HIV. J Clin Exp Neuropsychol 2004;
26:759–778.
14. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M,
et al. Updated research nosology for HIV-associated neuro-
cognitive disorders. Neurology 2007; 69:1789–1799.
15. Hamaker ME, Jonker JM, deRooij SE, Vos AG, Smorenburg CH,
vanMunster BD. Frailty screening methods for predicting out-
come of a comprehensive geriatric assessment in elderly pa-
tients with cancer: a systematic review. Lancet Oncol 2012;
13:e437–e444.
16. Erlandson KM, Allshouse AA, Jankowski CM, Duong S, Ma-
Whinney S, KohrtWM, Campbell TB.Comparison of functional
status instruments in HIV-infected adults on effective antire-
troviral therapy. HIV Clinical Trials 2012; 13:324–334.
17. Vetrano DL, Palmer K, Marengoni A, Marzetti E, Lattanzio F,
Roller-Wirnsberger R, et al. Frailty and multimorbidity: a
systematic review and meta-analysis. J Gerontol A Biol Sci
Med Sci 2018. doi: 10.1093/gerona/gly110. [Epub ahead of
print].
18. Rodriguez-Manas L, Feart C, Mann G, Vina J, Chatterji S,
Chodzko-ZajkoW, et al., FOD-CC group (Appendix 1). Search-
ing for an operational definition of frailty: a Delphi method
based consensus statement. The frailty operative definition-
consensus conference project. J Gerontol A Biol Sci Med Sci
2012; 68:62–67.
19. Robinson-Papp J, Byrd D, Rivera-Mindt M, Oden NL, Simpson
DM, Morgello S, Manhattan HIV Brain Bank. Motor function
and human immunodeficiency virus-associated cognitive im-
pairment in a highly active antiretroviral therapy-era cohort.
Arch Neurol 2008; 65:1096–1101.
20. Elicer IM, Byrd D, Clark US, Morgello S, Robinson-Papp J.
Motor function declines over time in human immunodefi-
ciency virus and is associated with cerebrovascular disease,
while HIV-associated neurocognitive disorder remains stable.
J Neurovirol 2018; 24:514–522.
21. Albers MW, Gilmore GC, Kaye J, Murphy C, Wingfield A,
Bennett DA, et al. At the interface of sensory and motor
dysfunctions and Alzheimer’s disease. Alzheimers Dement
2015; 11:70–98.
22. Fleischman DA, Yang J, Arfanakis K, Arvanitakis Z, Leurgans SE,
Turner AD, et al. Physical activity, motor function, and white
matter hyperintensity burden in healthy older adults. Neurol-
ogy 2015; 84:1294–1300.
23. Gouw AA, vanStraaten EC, Barkhof F, Ferro JM, Baezner H,
Pantoni L, et al., LADIS Study Group. Simple versus complex
assessment of white matter hyperintensities in relation to
physical performance and cognition: the LADIS study. J Neurol
2006; 253:1189–1196.
24. Biesbroek JM, Weaver NA, Biessels GJ. Lesion location and
cognitive impact of cerebral small vessel disease. Clin Sci 2017;
131:715–728.
25. Meyer ACL, Boscardin WJ, Kwasa JK, Price RW. Is it time to
rethink how neuropsychological tests are used to diagnosemild
forms of HIV-associated neurocognitive disorders? Impact of
false-positive rates on prevalence and power.Neuroepidemiol-
ogy 2013; 41:208–216.
26. Grant I, Franklin DR Jr, Deutsch R, Woods SP, Vaida F, Ellis RJ,
et al., CHARTER Group. Asymptomatic HIV-associated neuro-
cognitive impairment increases risk for symptomatic decline.
Neurology 2014; 82:2055–2062.
27. Levine AJ, Martin E, Sacktor N, Munro C, Becker J, Multicenter
AIDS Cohort Study-Neuropsychology Working Group. Predic-
tors and impact of self-reported suboptimal effort on estimates
of prevalence of HIV-associated neurocognitive disorders. J
Acquir Immune Defic Syndr 2017; 75:203–210.
28. Sacktor N, Skolasky RL, Seaberg E, Munro C, Becker JT, Martin
E, et al. Prevalence of HIV-associated neurocognitive disorders
in the Multicenter AIDS Cohort Study. Neurology 2016;
86:334–340.
29. Nichols MJ, Gates TM, Soares JR, Moffat KJ, Rae CD, Brew BJ,
Cysique LA. Atrophic brain signatures of mild forms of neu-
rocognitive impairment in virally suppressed HIV infection.
AIDS 2019; 33:55–66.
30. Charbek D, Espiritu JR, Nayak R, Morley JE. Frailty, comorbid-
ity, and COPD. J Nutr Health Aging 2018; 22:876–879.
31. Sinclair AJ, Abdelhafiz AH, Rodriguez-Manas L. Frailty and
sarcopenia - newly emerging and high impact complications
of diabetes. J Diabetes Complications 2017; 31:1465–1473.
32. Fatukasi TV, Edmonds A, Gustafson DR, Cole SR, Edwards JK,
Bolivar H, et al. Prevalence and 1-year incidence of frailty
among women with and without HIV in the Women’s Inter-
agency HIV Study. AIDS 2019; 33:357–361.
Frailty in HIV Morgello et al. 1611
